On August 30, CR Sanjiu has basically completed the acquisition of Shandong Linqing Huawei Pharmaceutical Co., Ltd., with the business registration formalities currently under way.

Huawei Pharmaceutical, now a subsidiary of Dong'e Ejiao, specializes in the production of Chinese medicine preparations, with approvals for the production of 80 products, including Liuwei Dihuang Pill and Ejiao Yishou Koufuye. Huawei Pharmaceutical realized a turnover of 50 million yuan and a profit of approximately 10 million yuan. On June 22, CR Sanjiu announced that it was planning to acquire Huawei Pharmaceutical at a consideration of 80.7473 million yuan as a supplement for the listed company.